0
Correspondence |

Macrolides in AsthmaMacrolides in Asthma FREE TO VIEW

Andrew R. L. Medford, MBChB, BSc(Hons), DM, FCCP
Author and Funding Information

From the North Bristol Lung Centre, Southmead Hospital.

Correspondence to: Andrew R. L. Medford, MBChB, BSc(Hons), DM, FCCP, North Bristol Lung Centre, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, England; e-mail: andrewmedford@hotmail.com


Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2012 American College of Chest Physicians


Chest. 2012;141(2):569-570. doi:10.1378/chest.11-2364
Text Size: A A A
Published online

To the Editor:

The study by Peters et al1 (August 2011) demonstrating Mycoplasma pneumoniae community-acquired respiratory distress toxin in subjects with refractory asthma, provides a stronger rationale for use of macrolides in this setting, although it was not possible to eradicate this in all subjects. Could this toxin’s presence and its sometimes failed eradication potentially explain the observed, yet often unexplained and unpredictable, benefits of prolonged macrolide therapy in cases of refractory asthma when there is no apparent reflux or bronchiolitis? This would add further weight to the proposed mechanism of treatment of atypical infection2 in addition to the armamentarium of well-known prokinetic3 and antiinflammatory action4 of these drugs.

Peters J, Singh H, Brooks EG, et al. Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma. Chest. 2011;1402:401-407 [PubMed] [CrossRef]
 
Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest. 2007;1326:1962-1966 [PubMed]
 
Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;982:259-263 [PubMed]
 
Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;1385:1202-1212 [PubMed]
 

Figures

Tables

References

Peters J, Singh H, Brooks EG, et al. Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma. Chest. 2011;1402:401-407 [PubMed] [CrossRef]
 
Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest. 2007;1326:1962-1966 [PubMed]
 
Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;982:259-263 [PubMed]
 
Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;1385:1202-1212 [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543